Items where authors include "Han, C"

Article

Orbai, A-M, Coates, LC, Deodhar, A et al. (10 more authors) (2022) Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. The Patient: Patient Centered Outcomes Research, 15 (6). pp. 657-668. ISSN 1178-1653

Han, C, Wang, T, Wu, Y et al. (10 more authors) (2022) Compensatory mechanism of attention-deficit/hyperactivity disorder recovery in resting state alpha rhythms. Frontiers in Computational Neuroscience, 16. 883065. ISSN 1662-5188

Niemi, MEK, Karjalainen, J, Liao, RG et al. (3763 more authors) (2021) Mapping the human genetic architecture of COVID-19. Nature, 600 (7889). pp. 472-477. ISSN 0028-0836

Rahman, P, Mease, PJ, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (10 more authors) (2021) Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response—results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis. Arthritis Research and Therapy, 23 (1). 190. ISSN 1478-6354

Wang, H, Abbas, KM, Abbasifard, M et al. (725 more authors) (2020) Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. The Lancet, 396 (10258). pp. 1160-1203. ISSN 0140-6736

Wyrzykowski, Ł, Mróz, P, Rybicki, KA et al. (182 more authors) (2020) Full orbital solution for the binary system in the northern Galactic disc microlensing event Gaia16aye. Astronomy & Astrophysics, 633 (January 2020). A98. ISSN 0004-6361

Guo, L, Li, Z, Lyu, J et al. (6 more authors) (2019) On the Validation of a Multiple-Network Poroelastic Model Using Arterial Spin Labeling MRI Data. Frontiers in Computational Neuroscience, 13. 60. ISSN 1662-5188

Wang, X, Cawood, PA, Zhao, H et al. (6 more authors) (2018) Mercury anomalies across the end Permian mass extinction in South China from shallow and deep water depositional environments. Earth and Planetary Science Letters, 496. pp. 159-167. ISSN 1385-013X

Emery, P, Fleischmann, RM, Strusberg, I et al. (12 more authors) (2016) Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. Arthritis Care and Research, 68 (6). pp. 744-752. ISSN 2151-464X

Conference or Workshop Item

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 DISCOVER Program. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Orbai, A-M, Coates, L, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 DISCOVER-1 Trial. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Kavanaugh, A, Liu, Y, Deodhar, A et al. (8 more authors) (2021) Correlations Between Reductions in Fatigue Severity and Improvements in Physical Function and Clinical Response in Patients with Psoriatic Arthritis: Results from the Phase 3 Discover Program. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (9 more authors) (2021) Guselkumab-Treated Patients with Psoriatic Arthritis Achieved Clinically Meaningful Improvements in General Health Outcomes Measured with PROMIS-29 Through 52 Weeks: Results from the Phase 3 Discover-1 Trial. In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Rahman, P, Helliwell, P orcid.org/0000-0002-4155-9105, Deodhar, A et al. (6 more authors) (2021) In Phase-3 Trials Discover 1 & 2, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue after Adjustment for Clinical Response (ACR20). In: EULAR 2021 Virtual Congress (Rheumatology), 02-05 Jun 2021, Virtual.

Orbai, A-M, Coates, L, Deodhar, A et al. (8 more authors) (2020) Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from Phase-3 Psoriatic Arthritis Trial DISCOVER 1. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Orbai, AM, Coates, LC, Deodhar, A et al. (8 more authors) (2020) AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Rahman, P, Deodhar, A et al. (6 more authors) (2020) SAT0421 GUSELKUMAB DEMONSTRATED AN INDEPENDENT TREATMENT EFFECT ON FATIGUE AFTER ADJUSTMENT FOR CLINICAL RESPONSE (ACR20) IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM PHASE-3 TRIALS DISCOVER 1 & 2. In: EULAR 2020, 03-06 Jun 2020, Online.

Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Proceedings Paper

Gossec, L, Kirkham, B, Rahman, P et al. (4 more authors) (2018) Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .